Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the best drug stocks to buy according to analysts. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was downgraded to Hold from Buy by Jefferies on April 20, with the firm bringing the price target on the stock down to $22 from $30. Despite what it calls an “inexpensive valuation”, the firm cited new launches being “less impactful than expected” and a lack of meaningful upside catalysts for the downgrade.
For additional perspective, in its financial results for the three months and full year ended December 31, 2025, Amphastar Pharmaceuticals, Inc. reported net revenues of $183.1 million and $719.9 million, respectively. GAAP net income was $24.4 million, or $0.51 per share, and $98.1 million, or $2.03 per share, respectively, for fiscal Q4 and the full year. Management further reported that the adjusted non-GAAP net income came up to $34.2 million, or $0.73 per share, and $156.6 million, or $3.25 per share, respectively, for the quarter and full year.
Amphastar Pharmaceuticals, Inc. develops, manufactures, markets, and sells technically challenging generic and proprietary injectable, intranasal, inhalation, and insulin active pharmaceutical ingredients. The company’s operations are divided into the Finished Pharmaceutical Products and Active Pharmaceutical Ingredients segments.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
